Klaus-Michael Debatin

List of Publications by Citations

486 papers	32,042 citations	78 h-index	169 g-index
521 ext. papers	35,164 ext. citations	6.5 avg, IF	6.84 L-index

#	Paper	IF	Citations
486	Two CD95 (APO-1/Fas) signaling pathways. *EMBO Journal*, **1998**, 17, 1675-87	13	2351
485	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541	12.7	2160
484	Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science*, **1989**, 245, 301-5	33.3	1581
483	Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). *Nature*, **1995**, 373, 438-41	50.4	1493
482	Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. *Science*, **1995**, 268, 1347-9	33.3	1079
481	Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. *Nature*, **1995**, 375, 497-500	50.4	892
480	Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. *Nature Medicine*, **1996**, 2, 574-7	50.5	869
479	Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. *Nature Medicine*, **2002**, 8, 808-15	50.5	698
478	Cellular stress response and apoptosis in cancer therapy. *Blood*, **2001**, 98, 2603-14	2.2	669
477	Activation interferes with the APO-1 pathway in mature human T cells. *International Immunology*, **1993**, 5, 625-30	4.9	413
476	Death receptors in chemotherapy and cancer. *Oncogene*, **2004**, 23, 2950-66	9.2	408
475	Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. *International Journal of Obesity*, **2001**, 25, 8-15	5.5	392
474	Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. *Oncogene*, **2001**, 20, 5865-77	9.2	375
473	CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. *Journal of Neuroscience*, **1999**, 19, 3809-17	6.6	371
472	Apoptosis pathways in cancer and cancer therapy. *Cancer Immunology, Immunotherapy*, **2004**, 53, 153-9	7.4	363
471	Chemotherapy: targeting the mitochondrial cell death pathway. *Oncogene*, **2002**, 21, 8786-803	9.2	350
470	Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. *Oncogene*, **2002**, 21, 2283-94	9.2	329

469	The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. *Cancer Research*, **1997**, 57, 3823-9	10.1	297
468	Regulation of apoptosis in the immune system. *Current Opinion in Immunology*, **1994**, 6, 279-89	7.8	285
467	Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. *Journal of Biological Chemistry*, **1998**, 273, 33942-8	5.4	270
466	TRAIL/Apo-2-ligand-induced apoptosis in human T cells. *European Journal of Immunology*, **1998**, 28, 143-52	6.1	256
465	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. *Lancet, The*, **2012**, 379, 1301-9	40	246
464	TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. *Oncogene*, **2003**, 22, 3842-52	9.2	241
463	Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. *Cancer Research*, **1997**, 57, 4956-64	10.1	239
462	Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. *Cancer Research*, **2004**, 64, 337-46	10.1	234
461	Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. *EMBO Journal*, **1997**, 16, 6200-8	13	225
460	IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. *Oncogene*, **2002**, 21, 2295-308	9.2	220
459	Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. *Oncogene*, **2001**, 20, 1063-75	9.2	206
458	Activation of Akt predicts poor outcome in neuroblastoma. *Cancer Research*, **2007**, 67, 735-45	10.1	192
457	Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. *Circulation*, **2000**, 102, 915-20	16.7	183
456	Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. *Leukemia*, **1997**, 11, 1833-41	10.7	181
455	Cytotoxic drugs and the CD95 pathway. *Leukemia*, **1999**, 13, 1854-8	10.7	177
454	Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases). *Blood*, **1997**, 90, 3118-3129	2.2	176
453	Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. *Oncogene*, **2004**, 23, 6702-11	9.2	176
452	Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. *American Journal of Clinical Nutrition*, **2010**, 92, 5-15	7	162

451	Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. *European Journal of Immunology*, **1997**, 27, 1207-12	6.1	154
450	Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. *Cancer Research*, **1998**, 58, 4453-60	10.1	148
449	Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 8699-704	11.5	145
448	Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. *International Journal of Cancer*, **1999**, 82, 435-41	7.5	143
447	Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. *Cancer Research*, **2000**, 60, 3947-56	10.1	141
446	Targeting apoptosis pathways in cancer therapy. *Current Cancer Drug Targets*, **2004**, 4, 569-76	2.8	140
445	Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. *Laboratory Investigation*, **1993**, 69, 415-29	5.9	139
444	Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. *Cancer Research*, **2003**, 63, 3112-20	10.1	139
443	c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. *Molecular and Cellular Biology*, **2000**, 20, 575-82	4.8	138
442	Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. *Lancet, The*, **1990**, 335, 497-500	40	138
441	Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. *Cancer Research*, **2008**, 68, 7956-65	10.1	137
440	Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. *Cancer Research*, **2009**, 69, 2425-34	10.1	133
439	Impaired gastric acidification negatively affects calcium homeostasis and bone mass. *Nature Medicine*, **2009**, 15, 674-81	50.5	133
438	Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. *Cancer Research*, **2008**, 68, 6271-80	10.1	131
437	Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *American Journal of Medical Genetics, Part A*, **2017**, 173, 1017-1037	2.5	124
436	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. *Blood*, **2009**, 113, 1710-22	2.2	122
435	Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. *Medical and Pediatric Oncology*, **2000**, 35, 616-8		122
434	Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. *International Journal of Cancer*, **1998**, 76, 105-14	7.5	121

433	Biologically inactive leptin and early-onset extreme obesity. *New England Journal of Medicine*, **2015**, 372, 48-54	59.2	118
432	Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. *Cancer Detection and Prevention*, **2006**, 30, 217-23		116
431	SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. *Blood*, **2014**, 123, 281-9	2.2	115
430	Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. *Oncogene*, **2005**, 24, 6945-56	9.2	115
429	CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **1998**, 91, 3943-3951	2.2	114
428	Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. *Biochemistry*, **1999**, 38, 13906-11	3.2	114
427	Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. *Blood*, **2010**, 115, 1156-65	2.2	113
426	Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. *Cell Death and Differentiation*, **1998**, 5, 884-93	12.7	113
425	Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. *Blood*, **2000**, 95, 301-308	2.2	111
424	Posttraumatic stress, depression and anxiety among adult long-term survivors of cancer in adolescence. *European Journal of Cancer*, **2010**, 46, 1596-606	7.5	110
423	MycN sensitizes neuroblastoma cells for drug-induced apoptosis. *Oncogene*, **1999**, 18, 1479-86	9.2	109
422	Characterization of sonic hedgehog as a novel NF-kappaB target gene that promotes NF-kappaB-mediated apoptosis resistance and tumor growth in vivo. *FASEB Journal*, **2009**, 23, 21-33	0.9	108
421	Betulinic acid-induced apoptosis in leukemia cells. *Leukemia*, **2004**, 18, 1406-12	10.7	103
420	Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. *Cancer Cell*, **2004**, 5, 477-88	24.3	98
419	Activation of apoptosis pathways by anticancer treatment. *Toxicology Letters*, **2000**, 112-113, 41-8	4.4	91
418	Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. *Neoplasia*, **2009**, 11, 743-52	6.4	89
417	A new missense mutation in the leptin gene causes mild obesity and hypogonadism without affecting T cell responsiveness. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 2836-40	5.6	88
416	Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. *European Journal of Pediatrics*, **2003**, 162, 139-146	4.1	88

415	MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. *Oncogene*, **1998**, 17, 339-46	9.2	86
414	Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. *Journal of Pediatrics*, **1998**, 132, 790-4	3.6	86
413	Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. *Medical and Pediatric Oncology*, **1992**, 20, 497-505		86
412	Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease. *American Journal of Human Genetics*, **2011**, 88, 226-31	11	84
411	FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. *Brain Research*, **1999**, 826, 210-9	3.7	83
410	Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. *Blood*, **2007**, 109, 3595-602	2.2	79
409	Overcoming apoptosis resistance in high risk acute lymphoblastic leukemia by SMAC mimetics in a preclinical ALL xenograft model in vivo. *Molecular and Cellular Pediatrics*, **2014**, 1, A22	3.3	78
408	Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. *Cancer Research*, **2007**, 67, 1950-8	10.1	77
407	Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. *Blood*, **2001**, 98, 3066-73	2.2	77
406	Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling. *Journal of Virology*, **2014**, 88, 5152-64	6.6	75
405	Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells. *Journal of Biological Chemistry*, **2002**, 277, 44791-800	5.4	75
404	Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. *Clinical Cancer Research*, **2011**, 17, 4019-30	12.9	74
403	Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. *Cell Death and Differentiation*, **1999**, 6, 471-80	12.7	74
402	Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. *Gut*, **2011**, 60, 225-37	19.2	73
401	JNK/SAPK activity contributes to TRAIL-induced apoptosis. *Cell Death and Differentiation*, **1999**, 6, 130-5	12.7	72
400	Beta-carotene cleavage products after oxidation mediated by hypochlorous acid--a model for neutrophil-derived degradation. *Free Radical Biology and Medicine*, **2003**, 35, 1480-90	7.8	71
399	Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. *Cancer Research*, **2005**, 65, 7888-95	10.1	71
398	Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. *Biomedicines*, **2019**, 7,	4.8	69

397	Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. *FASEB Journal*, **2010**, 24, 1997-2009	0.9	69
396	Sensitization for anticancer drug-induced apoptosis by betulinic Acid. *Neoplasia*, **2005**, 7, 162-70	6.4	69
395	Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. *British Journal of Pharmacology*, **1999**, 128, 1361-9	8.6	69
394	Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. *Journal of Immunology*, **2010**, 184, 677-84	5.3	68
393	Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. *Cancer Biology and Therapy*, **2007**, 6, 278-87	4.6	68
392	Apoptosis signaling in tumor therapy. *Annals of the New York Academy of Sciences*, **2004**, 1028, 150-6	6.5	68
391	IGF-I- and IGFBP-3-expression in cultured human preadipocytes and adipocytes. *Hormone and Metabolic Research*, **2000**, 32, 555-9	3.1	68
390	TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. *Clinical Cancer Research*, **2010**, 16, 5734-49	12.9	67
389	Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. *European Journal of Cancer*, **2005**, 41, 786-98	7.5	66
388	Differential expression of APO-1 on human thymocytes: implications for negative selection?. *European Journal of Immunology*, **1994**, 24, 753-8	6.1	66
387	Inhibition of death-receptor mediated apoptosis in human adipocytes by the insulin-like growth factor I (IGF-I)/IGF-I receptor autocrine circuit. *Endocrinology*, **2004**, 145, 1849-59	4.8	65
386	Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. *Blood*, **2006**, 108, 3504-13	2.2	64
385	miR-146a-mediated suppression of the inflammatory response in human adipocytes. *Scientific Reports*, **2016**, 6, 38339	4.9	64
384	Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. *Cancer Cell*, **2011**, 19, 206-17	24.3	63
383	HIF-1-regulated glucose metabolism: a key to apoptosis resistance?. *Cell Cycle*, **2007**, 6, 790-2	4.7	63
382	Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. *Aids*, **1999**, 13, 779-89	3.5	63
381	Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. *Cancer Research*, **2005**, 65, 10502-13	10.1	62
380	Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. *JAMA Pediatrics*, **2021**, 175, 586-593	8.3	61

379	Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. *Cell Cycle*, **2014**, 13, 1560-70	4.7	60
378	NF-B is required for Smac mimetic-mediated sensitization of glioblastoma cells for rradiation-induced apoptosis. *Molecular Cancer Therapeutics*, **2011**, 10, 1867-75	6.1	60
377	In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. *Blood*, **2015**, 126, 1138-48	2.2	59
376	Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 1251-61	8.8	59
375	Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. *Oncogene*, **2004**, 23, 7611-20	9.2	58
374	Contributions of age, gender and insulin administration to weight gain in subjects with IDDM. *Diabetologia*, **1998**, 41, 542-7	10.3	56
373	Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)dentical and HLA-nonidentical stem cell transplantation. *Blood*, **2000**, 96, 4344-4349	2.2	55
372	Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. *International Journal of Cancer*, **2004**, 109, 661-7	7.5	54
371	Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. *Clinical Cancer Research*, **2011**, 17, 3233-47	12.9	53
370	FTO deficiency induces UCP-1 expression and mitochondrial uncoupling in adipocytes. *Endocrinology*, **2013**, 154, 3141-51	4.8	52
369	Cell death sensitization of leukemia cells by opioid receptor activation. *Oncotarget*, **2013**, 4, 677-90	3.3	52
368	Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. *Clinical Cancer Research*, **2011**, 17, 3204-18	12.9	52
367	Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 4239-56	5.6	52
366	Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. *Oncogene*, **2005**, 24, 2421-9	9.2	52
365	Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). *International Journal of Cancer*, **2000**, 88, 252-9	7.5	52
364	Inhibition of NF-B signaling ablates the invasive phenotype of glioblastoma. *Molecular Cancer Research*, **2013**, 11, 1611-23	6.6	51
363	A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. *Cancer Research*, **2009**, 69, 8977-86	10.1	51
362	Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. *Diabetic Medicine*, **2007**, 24, 1393-9	3.5	51

361	Leptin substitution results in the induction of menstrual cycles in an adolescent with leptin deficiency and hypogonadotropic hypogonadism. *Hormone Research in Paediatrics*, **2012**, 77, 127-33	3.3	50
360	Social outcomes of long-term survivors of adolescent cancer. *Psycho-Oncology*, **2010**, 19, 1277-84	3.9	50
359	Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. *Haematologica*, **2005**, 90, 19-24	6.6	49
358	Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. *International Journal of Cancer*, **2009**, 124, 1301-11	7.5	48
357	Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. *Oncogene*, **2008**, 27, 5169-81	9.2	48
356	Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. *Molecular Cancer Therapeutics*, **2013**, 12, 1783-95	6.1	47
355	Educational and vocational achievement among long-term survivors of adolescent cancer in Germany. *Pediatric Blood and Cancer*, **2011**, 56, 432-8	3	47
354	HLA-haploidentical blood progenitor cell transplantation in osteopetrosis. *Blood*, **2002**, 99, 3458-60	2.2	46
353	Persistent defective membrane trafficking in epithelial cells of patients with familial hemophagocytic lymphohistiocytosis type 5 due to STXBP2/MUNC18-2 mutations. *Pediatric Blood and Cancer*, **2013**, 60, 1215-22	3	45
352	Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 1571-7	4.7	45
351	Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. *Cancer Research*, **2006**, 66, 10016-23	10.1	45
350	Severe Early-Onset Obesity Due to Bioinactive Leptin Caused by a p.N103K Mutation in the Leptin Gene. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 3227-30	5.6	44
349	Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. *Carcinogenesis*, **2008**, 29, 519-27	4.6	44
348	High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. *Blood*, **1994**, 83, 3101-3	2.2	44
347	Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. *Blood*, **2017**, 130, 643-654	2.2	43
346	Monogenic forms of childhood obesity due to mutations in the leptin gene. *Molecular and Cellular Pediatrics*, **2014**, 1, 3	3.3	43
345	An inflammatory micro-environment promotes human adipocyte apoptosis. *Molecular and Cellular Endocrinology*, **2011**, 339, 105-13	4.4	43
344	Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. *Leukemia*, **1995**, 9, 815-20	10.7	43

343	Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia. *Scientific Reports*, **2019**, 9, 14670	4.9	42
342	Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children. *Bone Marrow Transplantation*, **1999**, 24, 575-81	4.4	42
341	Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 574-583.e5	11.5	41
340	Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. *European Journal of Pediatrics*, **1998**, 157, 972-7	4.1	41
339	Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. *Journal of Pediatric Endocrinology and Metabolism*, **2003**, 16, 1225-32	1.6	41
338	CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. *Advances in Cancer Research*, **1998**, 75, 251-73	5.9	41
337	Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. *Journal of Virology*, **1996**, 70, 6502-7	6.6	41
336	CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. *Experimental Hematology*, **1998**, 26, 844-50	3.1	41
335	Apoptosis pathways in neuroblastoma therapy. *Cancer Letters*, **2003**, 197, 131-5	9.9	40
334	Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment. *Diabetes Care*, **2004**, 27, 1207-8	14.6	40
333	Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. *Blood*, **2011**, 117, 4642-50	2.2	39
332	Corticosteroid-induced chemotherapy resistance in urological cancers. *Cancer Biology and Therapy*, **2006**, 5, 59-64	4.6	39
331	Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells. *Journal of Immunology*, **2003**, 171, 1172-82	5.3	39
330	Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. *Cell Death and Differentiation*, **1999**, 6, 652-60	12.7	39
329	Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. *Klinische Padiatrie*, **1999**, 211, 319-22	0.9	39
328	Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia. *Clinical Cancer Research*, **2015**, 21, 1353-9	12.9	38
327	Diversity of human leukemia xenograft mouse models: implications for disease biology. *Cancer Research*, **2011**, 71, 7141-4	10.1	38
326	Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. *Oncogene*, **2005**, 24, 7190-202	9.2	38

325	Correction of complete interferon-gamma receptor 1 deficiency by bone marrow transplantation. *Blood*, **2002**, 100, 4234-5	2.2	38
324	Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. *Blood*, **2018**, 132, 469-483	2.2	37
323	TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. *Journal of Endocrinology*, **2005**, 186, 377-85	4.7	37
322	Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect. *Journal of Neuro-Oncology*, **2015**, 122, 21-33	4.8	36
321	Differential function of Akt1 and Akt2 in human adipocytes. *Molecular and Cellular Endocrinology*, **2012**, 358, 135-43	4.4	36
320	Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. *Immunologic Research*, **2009**, 44, 35-41	4.3	36
319	Loss of enteroendocrine cells in autoimmune-polyendocrine-candidiasis-ectodermal-dystrophy (APECED) syndrome with gastrointestinal dysfunction. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E292-300	5.6	36
318	Signaling through death receptors in cancer therapy. *Current Opinion in Pharmacology*, **2004**, 4, 327-32	5.1	36
317	Objective assessment of smoking habits by urinary cotinine measurement in adolescents and young adults with type 1 diabetes. Reliability of reported cigarette consumption and relationship to urinary albumin excretion. *Diabetes Care*, **1998**, 21, 787-91	14.6	36
316	Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. *Leukemia*, **1999**, 13, 400-9	10.7	36
315	Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. *Blood*, **1996**, 88, 1741-6	2.2	36
314	TRAIL induces apoptosis and activation of NFkappaB. *European Cytokine Network*, **1998**, 9, 687-8	3.3	36
313	RIST: a potent new combination therapy for glioblastoma. *International Journal of Cancer*, **2015**, 136, E173-87	7.5	35
312	NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. *Oncogene*, **2007**, 26, 571-82	9.2	35
311	Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. *PLoS ONE*, **2013**, 8, e83128	3.7	35
310	Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. *BMC Cancer*, **2006**, 6, 61	4.8	34
309	Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. *International Journal of Cancer*, **2003**, 107, 929-40	7.5	34
308	Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha. *Oncogene*, **2000**, 19, 4255-62	9.2	34

307	Death receptor signaling in cancer therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2003**, 3, 253-62		34
306	Activation of the CD95 system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. *Pediatric Infectious Disease Journal*, **1997**, 16, 754-9	3.4	34
305	A paired comparison between glioblastoma "stem cells" and differentiated cells. *International Journal of Cancer*, **2016**, 138, 1709-18	7.5	34
304	A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. *Molecular and Cellular Therapies*, **2014**, 2, 32		33
303	Requirement of nuclear factor **B** for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. *Neoplasia*, **2011**, 13, 1162-70	6.4	32
302	Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. *International Journal of Cancer*, **2010**, 126, 2216-28	7.5	32
301	Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. *International Journal of Cancer*, **1997**, 72, 536-42	7.5	32
300	Apoptosis in hematological disorders. *Seminars in Cancer Biology*, **2003**, 13, 149-58	12.7	32
299	HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. *BMC Molecular Biology*, **2001**, 2, 8	4.5	32
298	Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. *Anti-Cancer Agents in Medicinal Chemistry*, **2014**, 14, 313-8	2.2	32
297	Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in. *Blood*, **2017**, 130, 875-880	2.2	31
296	Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. *International Journal of Cancer*, **2004**, 108, 580-7	7.5	31
295	The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. *Hormone and Metabolic Research* , **2005**, 37, 602-9	3.1	31
294	JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. *International Journal of Cancer*, **1999**, 80, 417-24	7.5	30
293	Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). *Blood*, **1997**, 90, 3118-29	2.2	30
292	Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis. *Cancer Research*, **2000**, 60, 3212-7	10.1	30
291	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. *Journal of Experimental Medicine*, **2009**, 206, 1379-93	16.6	29
290	DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. *Molecular Biology of the Cell*, **2008**, 19, 3283-9	3.5	29

289	HIPK2 associates with RanBPM. *Biochemical and Biophysical Research Communications*, **2002**, 297, 148-53	3.4	29
288	Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia. *Pediatric Blood and Cancer*, **2016**, 63, 242-7	3	29
287	Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue. *Frontiers in Pharmacology*, **2015**, 6, 79	5.6	28
286	LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis. *Clinical Cancer Research*, **2018**, 24, 5772-5783	12.9	28
285	Lesson from hypomorphic recombination-activating gene (RAG) mutations: Why asymptomatic siblings should also be tested. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1211-5	11.5	28
284	A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. *PLoS ONE*, **2015**, 10, e0131670	3.7	28
283	Rapid improvement of hepatic steatosis after initiation of leptin substitution in a leptin-deficient girl. *Hormone Research in Paediatrics*, **2013**, 79, 310-7	3.3	28
282	Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis. *Anti-Cancer Drugs*, **2013**, 24, 14-9	2.4	28
281	Comparative gene array analysis of progenitor cells from human paired deep neck and subcutaneous adipose tissue. *Molecular and Cellular Endocrinology*, **2014**, 395, 41-50	4.4	27
280	Central nervous system acute lymphoblastic leukemia: role of natural killer cells. *Blood*, **2015**, 125, 3420-31	2.1	27
279	Inhibition of JNK signaling diminishes early but not late cellular stress-induced apoptosis. *International Journal of Cancer*, **2003**, 107, 520-7	7.5	27
278	Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome. *Blood*, **2017**, 129, 2928-2938	2.2	26
277	Early childhood BMI trajectories in monogenic obesity due to leptin, leptin receptor, and melanocortin 4 receptor deficiency. *International Journal of Obesity*, **2018**, 42, 1602-1609	5.5	26
276	Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. *International Immunopharmacology*, **2012**, 13, 93-100	5.8	26
275	Life satisfaction in adult survivors of cancer during adolescence: what contributes to the latter satisfaction with life?. *Quality of Life Research*, **2011**, 20, 225-36	3.7	26
274	N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells. *Oncogene*, **2008**, 27, 3424-34	9.2	26
273	Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. *British Journal of Haematology*, **2008**, 142, 622-6	4.5	26
272	Role of CD95-mediated adipocyte loss in autoimmune lipodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1129-35	5.6	26

271	Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. *International Journal of Cancer*, **1994**, 58, 562-7	7.5	26
270	TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation. *Journal of Immunology*, **2014**, 193, 4021-31	5.3	25
269	Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia. *British Journal of Haematology*, **1998**, 102, 722-8	4.5	25
268	Modulation of TRAIL signaling for cancer therapy. *Vitamins and Hormones*, **2004**, 67, 275-90	2.5	25
267	Activation of apoptosis pathways by anticancer drugs. *Advances in Experimental Medicine and Biology*, **1999**, 457, 237-44	3.6	25
266	Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. *Blood*, **2000**, 95, 301-8	2.2	25
265	Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma. *Cancer Letters*, **2016**, 371, 79-89	9.9	24
264	IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. *Blood*, **2018**, 132, 1614-1617	2.2	24
263	Elevated UCP1 levels are sufficient to improve glucose uptake in human white adipocytes. *Redox Biology*, **2019**, 26, 101286	11.3	24
262	The effects of PI3K-mediated signalling on glioblastoma cell behaviour. *Oncogenesis*, **2017**, 6, 398	6.6	24
261	Killing me softly--future challenges in apoptosis research. *International Journal of Molecular Sciences*, **2014**, 15, 3746-67	6.3	24
260	Precision medicine in pediatric oncology. *Molecular and Cellular Pediatrics*, **2018**, 5, 6	3.3	24
259	GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death. *Cancer Letters*, **2013**, 329, 27-36	9.9	23
258	Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction. *Biochemical Society Transactions*, **1997**, 25, 405-10	5.1	23
257	CNS complications in children receiving chemotherapy or hematopoietic stem cell transplantation: retrospective analysis and clinical study of survivors. *Pediatric Blood and Cancer*, **2008**, 50, 331-6	3	23
256	Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. *Haematologica*, **2007**, 92, 674-7	6.6	23
255	Exploiting death receptor signaling pathways for tumor therapy. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2004**, 1705, 27-41	11.2	23
254	Trail (TNF-related apoptosis-inducing ligand) induces an inflammatory response in human adipocytes. *Scientific Reports*, **2017**, 7, 5691	4.9	22

253	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. *Molecular Cancer Therapeutics*, **2015**, 14, 889-98	6.1	22
252	Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. *Anti-Cancer Drugs*, **2011**, 22, 494-9	2.4	22
251	Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. *Bone Marrow Transplantation*, **2001**, 28, 93-6	4.4	22
250	CD95-induced apoptosis contributes to loss of primed/memory but not resting/naive T cells in children infected with human immunodeficiency virus type 1. *Pediatric Research*, **1997**, 41, 878-85	3.2	22
249	Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. *International Journal of Oncology*, **2006**, 28, 551-8	1	22
248	MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. *Medical and Pediatric Oncology*, **2000**, 35, 582-4		21
247	APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. *Leukemia*, **1994**, 8, 1825-33	10.7	21
246	APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. *Blood*, **1993**, 81, 2972-7	2.2	21
245	Natural killer resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. *Haematologica*, **2003**, 88, 509-21	6.6	21
244	Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children. *Cell Death and Differentiation*, **1998**, 5, 222-30	12.7	20
243	Conjugated linoleic acids promote human fat cell apoptosis. *Hormone and Metabolic Research*, **2007** , 39, 186-91	3.1	20
242	Murine models for experimental therapy of pediatric solid tumors with poor prognosis. *International Journal of Cancer*, **2001**, 92, 313-8	7.5	20
241	TRAIL (TNF-related apoptosis-inducing ligand) inhibits human adipocyte differentiation via caspase-mediated downregulation of adipogenic transcription factors. *Cell Death and Disease*, **2016** , 7, e2412	9.8	20
240	Compare and contrast: pediatric cancer versus adult malignancies. *Cancer and Metastasis Reviews*, **2019**, 38, 673-682	9.6	20
239	Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. *British Journal of Cancer*, **2020**, 122, 1146-1157	8.7	19
238	Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity. *International Journal of Cancer*, **2010**, 127, 1295-307	7.5	19
237	Cytochrome c-related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL. *Blood*, **2006**, 107, 4524-31	2.2	19
236	TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. *Cancer Gene Therapy*, **2002**, 9, 372-81	5.4	19

235	When apoptosis fails. *Current Biology*, **1992**, 2, 383-5	6.3	19
234	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. *Haematologica*, **2020**, 105, 170-181	6.6	19
233	Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. *British Journal of Pharmacology*, **2019**, 176, 3681-3694	8.6	18
232	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. *Cell Death and Disease*, **2019**, 10, 571	9.8	18
231	Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2009**, 44, 333-8	4.4	18
230	Spontaneous complete and sustained remission of a rearrangement CBP (16p13)-positive disseminated congenital myelosarcoma. *Annals of Hematology*, **2005**, 84, 274-5	3	18
229	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. *Leukemia*, **2020**, 34, 151-166	10.7	18
228	Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. *British Journal of Haematology*, **2017**, 179, 272-283	4.5	17
227	Generation of murine sympathoadrenergic progenitor-like cells from embryonic stem cells and postnatal adrenal glands. *PLoS ONE*, **2013**, 8, e64454	3.7	17
226	Downregulation of Increased CD95 (APO-1/Fas) Ligand in T Cells From Human Immunodeficiency Virus-Type 1–Infected Children After Antiretroviral Therapy. *Blood*, **1997**, 90, 886-887	2.2	17
225	Immunological mechanisms associated with long-term remission of human type 1 diabetes. *Diabetes/Metabolism Research and Reviews*, **2006**, 22, 184-9	7.5	17
224	Isolation and characterization of cDNAs for the protein kinase HIPK2. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2001**, 1518, 168-72		17
223	The serine/threonine kinase HIPK2 interacts with TRADD, but not with CD95 or TNF-R1 in 293T cells. *Biochemical and Biophysical Research Communications*, **2000**, 277, 513-7	3.4	16
222	Diagnosis of diabetes in cystic fibrosis and thalassemia major. *Diabetes Care*, **1998**, 21, 671-2	14.6	16
221	Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. *Leukemia*, **1999**, 13, 410-8	10.7	16
220	MDSCs are induced after experimental blunt chest trauma and subsequently alter antigen-specific T cell responses. *Scientific Reports*, **2017**, 7, 12808	4.9	15
219	Up-regulation of Bcl-2 during adipogenesis mediates apoptosis resistance in human adipocytes. *Molecular and Cellular Endocrinology*, **2014**, 382, 368-376	4.4	15
218	Downregulation of FLIP by cycloheximide sensitizes human fat cells to CD95-induced apoptosis. *Experimental Cell Research*, **2011**, 317, 2200-9	4.2	15

217	Targeting inhibitor of apoptosis proteins (IAPs) for diagnosis and treatment of human diseases. *Recent Patents on Anti-Cancer Drug Discovery*, **2006**, 1, 81-9	2.6	15
216	Molecular determinants of apoptosis induced by cytotoxic drugs. *Klinische Padiatrie*, **1998**, 210, 148-52	0.9	15
215	Suppression of growth hormone by oral glucose in the evaluation of tall stature. *Hormone Research in Paediatrics*, **1999**, 51, 20-4	3.3	15
214	Activation of macrophages by lymphokines from T-cell clones: evidence for different macrophage-activating factors. *Molecular Immunology*, **1984**, 21, 1267-76	4.3	15
213	Cell Death Induction in Cancer Therapy - Past, Present, and Future. *Critical Reviews in Oncogenesis*, **2016**, 21, 253-267	1.3	15
212	Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. *Cell Death and Differentiation*, **1996**, 3, 185-9	12.7	15
211	Compound heterozygous and homozygous mutations of the TSHbeta gene as a cause of congenital central hypothyroidism in Europe. *Hormone Research in Paediatrics*, **2004**, 62, 149-55	3.3	14
210	Familial polycythemia vera with Budd-Chiari syndrome in childhood. *British Journal of Haematology*, **2003**, 123, 346-52	4.5	14
209	Induction of adipocyte differentiation by a thiazolidinedione in cultured, subepidermal, fibroblast-like cells of an infant with congenital generalized lipodystrophy. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 2384-90	5.6	14
208	TNF-related apoptosis-inducing ligand promotes human preadipocyte proliferation via ERK1/2 activation. *FASEB Journal*, **2015**, 29, 3065-75	0.9	13
207	Novel Approaches to Apoptosis-Inducing Therapies. *Advances in Experimental Medicine and Biology*, **2016**, 930, 173-204	3.6	13
206	Modulation of apoptosis signaling for cancer therapy. *Archivum Immunologiae Et Therapiae Experimentalis*, **2006**, 54, 173-5	4	13
205	Suicide gene therapy for pediatric tumors. *Journal of Molecular Medicine*, **2001**, 78, 598-612	5.5	13
204	Angiotensin I converting enzyme and angiotensinogen gene polymorphisms related to 24-h blood pressure in paediatric type I diabetes mellitus. *European Journal of Pediatrics*, **1999**, 158, 18-23	4.1	13
203	CD57(high) neuroblastoma cells have aggressive attributes ex situ and an undifferentiated phenotype in patients. *PLoS ONE*, **2012**, 7, e42025	3.7	13
202	Radiation and Brain Tumors: An Overview. *Critical Reviews in Oncogenesis*, **2018**, 23, 119-138	1.3	13
201	Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. *Blood Advances*, **2019**, 3, 862-868	7.8	13
200	TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. *Leukemia*, **2021**, 35, 389-403	10.7	13

199	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. *Vaccines*, **2021**, 9,	5.3	13
198	Teneurin-2 (TENM2) deficiency induces UCP1 expression in differentiating human fat cells. *Molecular and Cellular Endocrinology*, **2017**, 443, 106-113	4.4	12
197	Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?. *Leukemia*, **2020**, 34, 2305-2316	10.7	12
196	MCM3AP and POMP Mutations Cause a DNA-Repair and DNA-Damage-Signaling Defect in an Immunodeficient Child. *Human Mutation*, **2016**, 37, 257-68	4.7	12
195	CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes. *Cancer Immunology, Immunotherapy*, **2005**, 54, 655-62	7.4	12
194	Drug-induced apoptosis in osteosarcoma cell lines is mediated by caspase activation independent of CD95-receptor/ligand interaction. *Journal of Orthopaedic Research*, **2000**, 18, 10-7	3.8	12
193	The role of CD95 system in chemotherapy. *Drug Resistance Updates*, **1999**, 2, 85-90	23.2	12
192	Considering the Experimental use of Temozolomide in Glioblastoma Research. *Biomedicines*, **2020**, 8,	4.8	11
191	Estimated prevalence of potentially damaging variants in the leptin gene. *Molecular and Cellular Pediatrics*, **2017**, 4, 10	3.3	11
190	Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach. *Scientific Reports*, **2018**, 8, 5527	4.9	11
189	Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. *Blood*, **2018**, 131, 2929-2942	2.2	11
188	Establishment of lipofection for studying miRNA function in human adipocytes. *PLoS ONE*, **2014**, 9, e98033	3.7	11
187	Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma **2006**, 29, 1295		11
186	HDAC inhibitors: double edge sword for TRAIL cancer therapy?. *Cancer Biology and Therapy*, **2005**, 4, 1113-5	4.6	11
185	CD95 (APO-1/Fas) expression on naive CD4(+) T cells increases with disease progression in HIV-infected children and adolescents: effect of highly active antiretroviral therapy (HAART). *Pediatric Research*, **2001**, 49, 101-10	3.2	11
184	Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults. *Infection*, **1995**, 23, 344-8	5.8	11
183	Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model. *Oncotarget*, **2015**, 6, 1382-95	3.3	11
182	Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis. *Cellular Oncology (Dordrecht)*, **2019**, 42, 287-301	7.2	10

181	Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. *Clinical Therapeutics*, **2006**, 28, 2094-101	3.5	10
180	Disproportionately elevated fasting proinsulin levels in normoglycemic patients with thalassemia major are correlated to the degree of iron overload. *Hormone Research in Paediatrics*, **2003**, 59, 73-8	3.3	10
179	Expression of CD69 on T-cells from HIV-1-infected children and adolescents increases with increasing viral load. *European Journal of Pediatrics*, **1999**, 158, 638-44	4.1	10
178	Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. *Blood*, **2000**, 95, 301-308	2.2	10
177	Monitoring of CD95 (APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. *Cell Death and Differentiation*, **1996**, 3, 299-305	12.7	10
176	Cell death-based treatment of childhood cancer. *Cell Death and Disease*, **2018**, 9, 116	9.8	9
175	Antiviral vaccines license T cell responses by suppressing granzyme B levels in human plasmacytoid dendritic cells. *Journal of Immunology*, **2013**, 191, 1144-53	5.3	9
174	Congenital neuroblastoma mimicking early onset sepsis. *European Journal of Pediatrics*, **2001**, 160, 436-8	4.1	9
173	mAb33 from transduction laboratories specifically binds human CD95-L. *Cell Death and Differentiation*, **2000**, 7, 129-30	12.7	9
172	A simple combined microdissection and aspiration device for the rapid procurement of single cells from clinical peripheral blood smears. *Journal of Clinical Pathology*, **1998**, 51, 233-6		9
171	Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/NHL cells is due to the expression of only low affinity receptors for IL-2. *Leukemia*, **1989**, 3, 566-71	10.7	9
170	Immunostimulatory functions of adoptively transferred MDSCs in experimental blunt chest trauma. *Scientific Reports*, **2019**, 9, 7992	4.9	8
169	Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. *Experimental Hematology*, **2014**, 42, 90-100	3.1	8
168	Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation. *Pediatric Research*, **2009**, 65, 163-8	3.2	8
167	Whole genome amplification of single cells from clinical peripheral blood smears. *Journal of Clinical Pathology*, **1997**, 50, 272-5		8
166	Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML. *Blood*, **2008**, 111, 2899-903	2.2	8
165	Digenic inheritance of hepatocyte nuclear factor-1alpha and -1beta with maturity-onset diabetes of the young, polycystic thyroid, and urogenital malformations. *Diabetes Care*, **2007**, 30, 1613-4	14.6	8
164	Growth inhibition of murine neuroblastoma cells by c-myc with cell cycle arrest in G2/M. *Cancer Biology and Therapy*, **2005**, 4, 181-6	4.6	8

163	Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. *Oncotarget*, **2016**, 7, 62799-62813	3.3	8
162	MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts. *Carcinogenesis*, **2014**, 35, 479-88	4.6	7
161	Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. *Archives of Disease in Childhood*, **2011**, 96, 1026-32	2.2	7
160	Novel homozygous AIRE mutation in a German patient with severe APECED. *Journal of Pediatric Endocrinology and Metabolism*, **2008**, 21, 1003-9	1.6	7
159	Sensitivity of CD4+ Peripheral Blood T Cells Toward Spontaneous and CD95 (APO-1/Fas)-Induced Apoptosis in Pediatric Human Immunodeficiency Virus Infection. *Blood*, **1999**, 94, 1829-1833	2.2	7
158	The RIST design: A molecularly targeted multimodal approach for the treatment of patients with relapsed and refractory neuroblastoma.. *Journal of Clinical Oncology*, **2013**, 31, 10017-10017	2.2	7
157	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. *Oncotarget* , **2016**, 7, 6620-5	3.3	7
156	Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells. *International Journal of Oncology*, **2018**, 53, 1881-1896	4.4	7
155	Late thymic deficiency after HLA-haploidentical hematopoietic stem cell transplantation for severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 1623-1626.e13	11.5	6
154	Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions. *Blood*, **2013**, 121, 556-65	2.2	6
153	Urticaria, fever, and hypofibrinogenemia. *Arthritis and Rheumatology*, **2014**, 66, 1377	9.5	6
152	Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice. *Haematologica*, **2014**, 99, 1050-61	6.6	6
151	Assignment of TRADD to human chromosome band 16q22 by in situ hybridization. *Cytogenetic and Genome Research*, **2001**, 92, 347-8	1.9	6
150	APO-1 (CD95) and Bcl-2: determinants of cell death in the human thymus. *Research in Immunology*, **1994**, 145, 146-51; discussion 155-8		6
149	Robust and durable serological response following pediatric SARS-CoV-2 infection.. *Nature Communications*, **2022**, 13, 128	17.4	6
148	Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56CD16NKp80 and Express KIR2DL2/DL3 and KIR3DL1. *Frontiers in Immunology*, **2021**, 12, 640672	8.4	6
147	Persisting enteropathy and disturbed adaptive mucosal immunity due to MHC class II deficiency. *Clinical Immunology*, **2019**, 203, 125-133	9	5
146	Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease. *BMC Gastroenterology*, **2013**, 13, 77	3	5

145	Chronic lymphocytic leukemia: keeping cell death at bay. *Cell*, **2007**, 129, 853-5	56.2	5
144	AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. *Annals of Hematology*, **2005**, 84, 774-80	3	5
143	T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy. *Blood*, **2001**, 97, 1898-901	2.2	5
142	Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. *Vaccine*, **2020**, 38, 1810-1817	4.1	5
141	Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia. *International Journal of Cancer*, **2020**, 146, 3219-3231	7.5	5
140	miR-146a regulates insulin sensitivity via NPR3. *Cellular and Molecular Life Sciences*, **2021**, 78, 2987-3003	10.3	5
139	Cell death: From initial concepts to pathways to clinical applications - Personal reflections of a clinical researcher. *Biochemical and Biophysical Research Communications*, **2017**, 482, 445-449	3.4	4
138	The limitations of targeting MEK signalling in Glioblastoma therapy. *Scientific Reports*, **2020**, 10, 7401	4.9	4
137	Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis. *Molecular and Cellular Pediatrics*, **2018**, 5, 1	3.3	4
136	Toll-like 4 receptor variant, Asp299Gly, and reduced risk of hemorrhagic cystitis after hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 958-63	4.7	4
135	Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic. *Klinische Padiatrie*, **2009**, 221, 332-8	0.9	4
134	Analysis of the CD95 ligand gene in 20 children with autoimmune lymphoproliferative syndrome (ALPS). *Blood*, **2006**, 108, 3622-3; author reply 3623	2.2	4
133	T cell activation deficiencies. *Clinical Immunology and Immunopathology*, **1995**, 76, S163-4		4
132	Migration of Acute Lymphoblastic Leukemia Cells into the Central Nervous System Is Regulated By VEGF. *Blood*, **2015**, 126, 2634-2634	2.2	4
131	microRNA-27a-3p but Not -5p Is a Crucial Mediator of Human Adipogenesis. *Cells*, **2021**, 10,	7.9	4
130	Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies. *Oncolytic Virotherapy*, **2018**, 7, 37-41	6	4
129	Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system **1998**, 76, 105		4
128	In vitro-generated alloantigen-specific Th9 cells mediate antileukemia cytotoxicity in the absence of graft-versus-host disease. *Leukemia*, **2020**, 34, 1943-1948	10.7	3

127	Comment in Response to "Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy etc. by B. Kaina". *Biomedicines*, **2020**, 8,	4.8	3
126	Leukemia reconstitution is driven by cells in early cell cycle and low metabolic state. *Haematologica*, **2018**, 103, 1008-1017	6.6	3
125	Age- and BMI-Associated Expression of Angiogenic Factors in White Adipose Tissue of Children. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
124	Apoptosis Signaling Pathways in Anticancer Therapy. *Current Cancer Therapy Reviews*, **2008**, 4, 14-20	0.4	3
123	Screening, identification, and functional analysis of three novel missense mutations in the TRADD gene in children with ALL and ALPS. *Pediatric Blood and Cancer*, **2008**, 51, 616-20	3	3
122	The TRAIL Receptor-Ligand System: Biochemistry of Apoptosis Induction, Therapeutic Potential for Cancer Treatment and Physiological Function31-92		3
121	A sensitive, non-radioactive and fast method for detection of JNK/SAPK activity in leukemic T cells. *Leukemia*, **2000**, 14, 1859-60	10.7	3
120	Juvenile hyaline Fibromatose Differentialdiagnose der Arthrogryposis multiplex. *Monatsschrift Fur Kinderheilkunde*, **1999**, 147, 473-476	0.2	3
119	APO-I-mediated apoptosis in normal and malignant lymphocytes. *Biochemical Society Transactions*, **1994**, 22, 598-600	5.1	3
118	A Novel B Cell Precursor ALL Cell Line (018Z) with Prominent Neurotropism and Isolated CNS Leukemia in a NOD/SCID/huALL Xenotransplantation Model.. *Blood*, **2009**, 114, 1630-1630	2.2	3
117	Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantion: Results of a Prospective Phase II/III Randomized, Multicenter Study.. *Blood*, **2009**, 114, 653-653	2.2	3
116	CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia. *Blood*, **1998**, 91, 3943-3951	2.2	3
115	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Households with Children, Southwest Germany, May-August 2020. *Emerging Infectious Diseases*, **2021**, 27, 3009-3019	10.2	3
114	Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. *Blood*, **2021**,	2.2	3
113	Typically asymptomatic but with robust antibody formation: Children unique humoral immune response to SARS-CoV-2		3
112	Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.. *EMBO Molecular Medicine*, **2022**, e14901	12	3
111	Varicella-zoster-virus vaccination of immunosuppressed children with inflammatory bowel disease or autoimmune hepatitis: A prospective observational study. *Vaccine*, **2020**, 38, 8024-8031	4.1	2
110	Physiologische Relevanz des braunen Fettgewebes beim Menschen. *Monatsschrift Fur Kinderheilkunde*, **2017**, 165, 502-509	0.2	2

109	HSCT cures ADA2 deficiency. *Blood*, **2017**, 130, 2582-2583	2.2	2
108	Cancer therapy: know your enemy?. *Molecular and Cellular Pediatrics*, **2014**, 1, 10	3.3	2
107	Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas **2006**, 28, 551		2
106	Cellular FLICE-inhibitory Protein: An Update120-156		2
105	Death Receptor Pathways As Targets for Anticancer Therapy **2005**, 57-78		2
104	Eradication of a dysfunctional HLA-haploidentical T cell system by a second HLA-identical BMT. *Bone Marrow Transplantation*, **2001**, 28, 993-5	4.4	2
103	Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL.. *Leukemia*, **2022**,	10.7	2
102	Treatment of Complete DiGeorge Syndrome by Repeat Transfusions of Blood Lymphocytes from an HLA-Identical Sibling Donor.. *Blood*, **2004**, 104, 1332-1332	2.2	2
101	Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. *Blood*, **2008**, 112, 857-857	2.2	2
100	Granzyme B Is a Key Regulator of Plasmacytoid Dendritic Cell Immunogenicity. *Blood*, **2014**, 124, 4127-4127	12.7	2
99	Downregulation of Increased CD95 (APO-1/Fas) Ligand in T Cells From Human Immunodeficiency Virus-Type 1–Infected Children After Antiretroviral Therapy. *Blood*, **1997**, 90, 886-887	2.2	2
98	Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)–identical and HLA-nonidentical stem cell transplantation. *Blood*, **2000**, 96, 4344-4349	2.2	2
97	Darwinian Principles in Cancer Therapy. *European Oncology and Haematology*, **2014**, 10, 116	0.1	2
96	CD95 (APO-1/Fas) in hematopoietic diseases. *Results and Problems in Cell Differentiation*, **1998**, 24, 157-174	1.4	2
95	IFN-γ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway		2
94	Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression		2
93	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. *Rheumatology International*, **2021**, 41, 911-920	3.6	2
92	Successful hematopoietic stem cell transplantation in a 4-1BB deficient patient with EBV-induced lymphoproliferation. *Clinical Immunology*, **2021**, 222, 108639	9	2

91	Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids. *Oncology Letters*, **2018**, 16, 6181-6187	2.6	2
90	MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 695225	5.7	2
89	TRAIL/Apo-2-ligand-induced apoptosis in human T cells **1998**, 28, 143		2
88	Role of apoptosis in congenital hematologic disorders and bone marrow failure. *Reviews in Clinical and Experimental Hematology*, **2003**, 7, 57-71		2
87	Dataset of clinical, immunohistopathological and laboratory features of patients with MHC II deficiency suffering from enteropathy. *Data in Brief*, **2019**, 26, 104446	1.2	1
86	Apoptosis-Inducing Cellular Vehicles for Cancer Gene Therapy **2007**, 279-302		1
85	Tumorstammzellen: Grundlagen, klinische Implikationen und Kontroversen. *Onkopipeline*, **2008**, 1, 91-100		1
84	Therapeutic Modulation of Apoptosis in Cancer Therapy849-861		1
83	Mouse Models in Cancer Research671-701		1
82	Clinical Quiz. A patient with hematuria and cystic renal mass. *Pediatric Nephrology*, **2006**, 21, 324-7	3.2	1
81	Apoptosis in Drug Response. *Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics*, **2003**, 1, 9-16		1
80	Combination of Chemotherapy and Death Ligands in Cancer Therapy **2005**, 355-366		1
79	Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy.. *Pharmaceuticals*, **2022**, 15,	5.2	1
78	Biomarker Profile for Prediction of Patient Response to Smac Mimetic Monotherapy in Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 2082-2082	2.2	1
77	Synergistic Activity of ABT-199 with Conventional Chemotherapy and Dinaciclib in B-Cell Precursor Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 2631-2631	2.2	1
76	Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 903-903	2.2	1
75	Inhibiting Casein Kinase 2 Sensitizes Acute Lymphoblastic Leukemia Cells to Venetoclax Via MCL1 Degradation. *Blood Advances*, **2021**,	7.8	1
74	Compound Heterozygeous RAG-1 Mutations in 2 Patients Presenting with Chronic Disfiguring Granulomatous Skin Lesions.. *Blood*, **2005**, 106, 3898-3898	2.2	1

73	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. *Blood*, **2019**, 134, 1507-1507	2.2	1
72	Molecular Control of Programmed Cell Death in HIV Infection **1999**, 99-114		1
71	A Stable and Reproducible Xenotransplant Model for AML.. *Blood*, **2009**, 114, 1005-1005	2.2	1
70	CD90 Is Dispensable for White and Beige/Brown Adipocyte Differentiation. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
69	Lipodystrophy as a Late Effect after Stem Cell Transplantation. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
68	MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. *Blood*, **2021**, 138, 1953-1965	2.2	1
67	Matched Family Donor Lymphocyte Infusions as First Cellular Therapy for Patients with Severe Primary T Cell Deficiencies. *Transplantation and Cellular Therapy*, **2021**, 27, 93.e1-93.e8		1
66	JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF- **1999**, 80, 417		1
65	Cell death in T- and B-cell development. *Annals of Hematology*, **2001**, 80 Suppl 3, B29-31	3	1
64	Occult thyroid pathology in a child with acquired immunodeficiency syndrome. Case report and review of the drug-related pathology in pediatric acquired immunodeficiency syndrome. *Pathology and Oncology Research*, **2000**, 6, 227-32	2.6	0
63	Differential uptake of three clinically relevant allergens by human plasmacytoid dendritic cells. *Clinical and Molecular Allergy*, **2021**, 19, 23	3.7	0
62	Graft-Versus-Host Disease Prevention by -Generated Myeloid-Derived Suppressor Cells Is Exclusively Mediated by the CD11b+CD11c+ MDSC Subpopulation. *Frontiers in Immunology*, **2021**, 12, 754316	8.4	0
61	Urine Proteomic Analysis Reveals Disease-Specific Patterns in Pediatric Patients with Classical Hodgkin's Disease(HD). an Addon Study to the Euronet-PHL-C2 Trial. *Blood*, **2019**, 134, 2804-2804	2.2	0
60	Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response. *Blood*, **2016**, 128, 1081-1081	2.2	0
59	What Animal Cancers teach us about Human Biology. *Theranostics*, **2021**, 11, 6682-6702	12.1	0
58	Latent TGF binding proteins regulate UCP1 expression and function via TGF . *Molecular Metabolism*, **2021**, 53, 101336	8.8	0
57	Modeling acute graft-versus-host disease (aGVHD) in murine bone marrow transplantation (BMT) models with MHC disparity.. *Methods in Cell Biology*, **2022**, 168, 19-39	1.8	0
56	Molecular and Cellular Pediatrics. *Molecular and Cellular Pediatrics*, **2014**, 1, 4	3.3	

55	Mitochondrial genome variants in non-remitting ALL of childhood. *British Journal of Haematology*, **2011**, 155, 626-9	4.5
54	No conference critique. *Nature*, **1998**, 393, 618	50.4
53	Lymphohematopoiesis in health and diseaseedited by Nydia G. Testa, Brian I. Lord, T. Michael Dexter. *Cell Death and Differentiation*, **1998**, 5, 340-341	12.7
52	Cell Death in Cancer and Cancer Therapy **2005**, 461-481	
51	Current Therapeutic Strategies Targeting Caspases in Disease862-890	
50	Exploiting Apoptosis Pathways for Glioblastoma Therapy1033-1048	
49	Role of Mitochondrial Proteins in Apoptosis185-221	
48	Omi/HtrA2: A Mitochondrial Serine Protease Regulating Cellular Life and Death222-232	
47	p53-mediated Apoptosis: A Multifaceted Story517-535	
46	Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers. *Current Signal Transduction Therapy*, **2006**, 1, 179-190	0.8
45	Apoptosis Induced by DNA-damaging Agents799-821	
44	Apoptosesignaltransduktion und M□glichkeiten der therapeutischen Modulation. *Onkologe*, **2004**, 10, S62-S63	0.1
43	Genes Involved in Apoptosis Regulation: Implications for Cancer Therapy. *Current Genomics*, **2005**, 6, 609-611	2.6
42	Severe persistent neuropsychiatric toxicity after a human leucocyte antigen-non-identical peripheral blood stem cell transplantation (total body irradiation, etoposide, thiotepa) and interleukin 2-based experimental therapy for poor prognosis relapse acute lymphoblastic leukaemia. *British Journal of Haematology*, **2001**, 114, 487-9	4.5
41	Sensitivity and Resistance to Apoptosis in the APO-1 (Fas/CD95) System. *Oncology Research and Treatment*, **1996**, 19, 3-5	2.8
40	Depressed mediator release by inflammatory exudate cells in immunized rats following antigen challenge. *Agents and Actions*, **1981**, 11, 627-8	
39	Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma.. *ACS Omega*, **2022**, 7, 5929-5936	3.9
38	Reply to Dr. Steven J. Russell. Interleukin-2 as an autocrine growth factor: feeding the antitumor response?. *Leukemia*, **1989**, 3, 829	10.7

37	Modulation of TRAIL Signaling for Cancer Therapy **2007**, 579-591	
36	Aktuelle Behandlungskonzepte f Hirntumoren im Kindes- und Jugendalter. *Onkologie Up2date*, **2020**, 2, 327-345	0
35	Resveratrol as Inhibitor of Cell Survival Signal Transduction. *Oxidative Stress and Disease*, **2005**, 105-117	
34	Everolimus Is Comparably Effective to Rapamycin Acting Synergistically with Imatinib in the Treatment of Constitutively Active Mutations of the Juxtamembrane Domain of c-Kit.. *Blood*, **2006**, 108, 1992-1992	2.2
33	Radioimmunotherapy for Myeloablation Before SCT in Paediatric Patients with Malignant and Non-Malignant Diseases.. *Blood*, **2007**, 110, 624-624	2.2
32	Synergistic Activity of the MCL-1-Specific Inhibitor S63845 with Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 1416-1416	2.2
31	Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia. *Blood*, **2019**, 134, 3954-3954	2.2
30	Biomarkers of DNA Damage Response Enable Flow Cytometry-Based Diagnostic to Identify Inborn DNA Repair Defects in Primary Immunodeficiencies. *Journal of Clinical Immunology*, **2021**, 1	5.7
29	Diagnostics and Experimental Therapy **1998**, 89-118	
28	Diagnostik und Experimentelle Therapie **1998**, 91-122	
27	Role of CD95 (APO-1/Fas) System in Chemotherapy **1999**, 175-187	
26	Effective in Vivo Targeting of BCP-ALL in a NOD/SCID/huALL Mouse Model By CD70 Directed Immunotherapy. *Blood*, **2014**, 124, 970-970	2.2
25	TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib. *Blood*, **2016**, 128, 737-737	2.2
24	Lysosomal Cell Death and Apoptosis Crosstalk - Synergistic Role in Bcl-2 Inhibitor (ABT-263) Mediated Cell Death in B-Cell Precursor Acute Lymphoblastic Leukemia. *Blood*, **2016**, 128, 1584-1584	2.2
23	FOXO1 Is Involved in the Regulation of B-Cell Precursor Acute Lymphoblastic Leukemia Survival and Serves As a Novel Target for Directed Therapy. *Blood*, **2016**, 128, 4020-4020	2.2
22	Single-Cell Phospho-Profiling in Pediatric Acute Lymphoblastic Leukemia (ALL) Reveals Constitutive and Cytokine Induced Specific Signatures Involving Stat5. *Blood*, **2008**, 112, 2511-2511	2.2
21	Deficient Apoptosis Signaling in Primary Pediatric BCP-ALL Xenograft Cells Determines the Kinetic of Engraftment in Vivo in a NOD/SCID Model and Patient Outcome. *Blood*, **2008**, 112, 2509-2509	2.2
20	Time to Leukemia (TTL) in NOD/SCID Mice Determines Patient Outcome and Is Characterized by a 5 Genes Signature Associated with Relapse. *Blood*, **2008**, 112, 755-755	2.2

19	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. *Journal of Cell Biology*, **2009**, 185, i13-i13	7.3
18	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.. *Blood*, **2009**, 114, 731-731	2.2
17	Single-Cell Phospho-Profiling in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Reveals Signaling Differences in Cytogenetic and Prognostic Subgroups.. *Blood*, **2009**, 114, 2653-2653	2.2
16	Xenografts of Pediatric Acute Lymphoblastic Leukemia Retain the Gene Expression Pattern From the Diagnostic Material They Originated From Over Serial Passages.. *Blood*, **2009**, 114, 1629-1629	2.2
15	Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T Cell Expansion.. *Blood*, **2009**, 114, 2674-2674	2.2
14	XIAP Inhibitors Present a Promising New Strategy to Sensitize Childhood Acute Leukemia Cells for Chemotherapy-Induced Apoptosis.. *Blood*, **2009**, 114, 3791-3791	2.2
13	Polymorphisms of Exon 10 in Stem Cell Factor Receptor KIT Are Associated with a Significantly Improved Relapse-Free Survival in Childhood AML.. *Blood*, **2009**, 114, 2636-2636	2.2
12	Genetic and Clinical Spectrum of Osteopetrosis.. *Blood*, **2009**, 114, 1087-1087	2.2
11	Apoptose **2010**, 151-161	
10	Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation. *Blood*, **2010**, 116, 3243-3243	2.2
9	Activation of Acute Lymphocytic Leukemia Blasts with CpG ODN, IL-4 and CD40 Ligand Facilitates Enhanced Anti-Leukemic CTL Responses. *Blood*, **2010**, 116, 3907-3907	2.2
8	Intact Apoptosis Signaling In Pediatric ALL Xenograft Leukemia Is Associated with Favorable Patient Outcome, Prolonged NOD/SCID Engraftment and Low Expression of Anti-Apoptotic Molecules. *Blood*, **2010**, 116, 2722-2722	2.2
7	Dihydrofolate Reductase Deficiency Is Caused by a Homozygous DHFR Mutation and Leads to Congenital Megaloblastic Anemia and Cerebral Folate Deficiency. *Blood*, **2010**, 116, 1006-1006	2.2
6	High Risk Acute Lymphoblastic Leukemia with Rapid NOD/SCID Engraftment Is Characterized by High Protein Expression of CYCLIN B, Beta-CATENIN, ANNEXIN I and Decreased PKC Alpha Activation. *Blood*, **2011**, 118, 1457-1457	2.2
5	Hyperactivated mTOR Signaling Is a Characteristic Feature of High Risk Acute Lymphoblastic Leukemia and Can Be Effectively Targeted in a Preclinical NOD/SCID/huALL Xenograft Mouse Model. *Blood*, **2011**, 118, 2572-2572	2.2
4	Regulation of Plasmacytoid Dendritic Cells by Commonly Used Anti-Viral Vaccines,. *Blood*, **2011**, 118, 3221-3221	2.2
3	CRLF2 Rearrangement Is Not Associated with Activated mTOR Pathway in NOD/SCID/huALL Xenograft Mouse Model.. *Blood*, **2012**, 120, 2518-2518	2.2
2	Rapid BCP-ALL Engraftment in NOD/SCID Mice Is Characterized by a High Leukemia Initiating Cell (LIC) Frequency.. *Blood*, **2012**, 120, 2985-2985	2.2

1 Leukemia Initiating Cells In Acute Lymphoblastic Leukemia Are Characterized By Low Metabolic Activity and Enriched In Early Cell Cycle. *Blood*, **2013**, 122, 4197-4197 2.2